MX2022013927A - Composiciones y metodos para tratar la epilepsia. - Google Patents
Composiciones y metodos para tratar la epilepsia.Info
- Publication number
- MX2022013927A MX2022013927A MX2022013927A MX2022013927A MX2022013927A MX 2022013927 A MX2022013927 A MX 2022013927A MX 2022013927 A MX2022013927 A MX 2022013927A MX 2022013927 A MX2022013927 A MX 2022013927A MX 2022013927 A MX2022013927 A MX 2022013927A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- treating epilepsy
- compositions
- administering
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2857—Seizure disorders; Epilepsy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063020245P | 2020-05-05 | 2020-05-05 | |
| PCT/US2021/030930 WO2021242493A2 (en) | 2020-05-05 | 2021-05-05 | Compositions and methods for treating epilepsy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022013927A true MX2022013927A (es) | 2022-11-30 |
Family
ID=78745740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022013927A MX2022013927A (es) | 2020-05-05 | 2021-05-05 | Composiciones y metodos para tratar la epilepsia. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240034775A1 (enExample) |
| EP (1) | EP4146276A4 (enExample) |
| JP (1) | JP2023524819A (enExample) |
| CN (1) | CN115996752B (enExample) |
| AU (1) | AU2021278819A1 (enExample) |
| CA (1) | CA3177879A1 (enExample) |
| MX (1) | MX2022013927A (enExample) |
| WO (1) | WO2021242493A2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201510316UA (en) | 2013-07-09 | 2016-01-28 | Annexon Inc | Anti-complement factor c1q antibodies and uses thereof |
| US12486322B2 (en) * | 2021-12-13 | 2025-12-02 | Annexon, Inc. | Anti-complement factor C1q antibodies with single binding arms and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2912396T3 (es) * | 2012-11-02 | 2022-05-25 | Bioverativ Usa Inc | Anticuerpos anti-C1s del complemento y uso de los mismos |
| SG11201510316UA (en) * | 2013-07-09 | 2016-01-28 | Annexon Inc | Anti-complement factor c1q antibodies and uses thereof |
| PL3215527T3 (pl) * | 2014-11-05 | 2025-04-28 | Annexon, Inc. | Humanizowane przeciwciała przeciwko czynnikowi dopełniacza C1Q i ich zastosowanie |
| JP6779876B2 (ja) * | 2014-11-19 | 2020-11-04 | ジェネンテック, インコーポレイテッド | 抗トランスフェリン受容体抗体及びその使用方法 |
| IL309260B2 (en) * | 2015-07-24 | 2025-01-01 | Gliknik Inc | Fusion proteins of human protein fragments to create ordered multimeric immunoglobulin FC preparations with enhanced complement binding |
| FI3380518T3 (fi) * | 2015-11-24 | 2026-05-29 | Annexon Inc | Antikomplementtitekijä-C1Q:n Fab-fragmentteja ja niiden käyttöjä |
| US20190161535A1 (en) * | 2016-05-09 | 2019-05-30 | Annexon, Inc. | Compositions and methods for treating spinal muscular atrophy |
| EP3487531A4 (en) * | 2016-07-19 | 2020-03-25 | Annexon, Inc. | TREATMENT OF FRONTO-TEMPORAL DEMENTIA |
| CN112867394B9 (zh) * | 2018-06-04 | 2024-12-06 | 马萨诸塞州渤健公司 | 具有降低的效应功能的抗vla-4抗体 |
| MX2021004819A (es) * | 2018-11-02 | 2021-06-08 | Annexon Inc | Composiciones y metodos para tratar lesiones cerebrales. |
| WO2020124013A1 (en) * | 2018-12-13 | 2020-06-18 | Gryphon Bio, Inc. | Combinatorial temporal biomarkers and precision medicines with detection and treatment methods for use in neuro injury, neuro disease, and neuro repair |
-
2021
- 2021-05-05 US US17/923,456 patent/US20240034775A1/en active Pending
- 2021-05-05 WO PCT/US2021/030930 patent/WO2021242493A2/en not_active Ceased
- 2021-05-05 CN CN202180032987.3A patent/CN115996752B/zh active Active
- 2021-05-05 JP JP2022567591A patent/JP2023524819A/ja active Pending
- 2021-05-05 EP EP21813355.1A patent/EP4146276A4/en active Pending
- 2021-05-05 CA CA3177879A patent/CA3177879A1/en active Pending
- 2021-05-05 AU AU2021278819A patent/AU2021278819A1/en active Pending
- 2021-05-05 MX MX2022013927A patent/MX2022013927A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN115996752A (zh) | 2023-04-21 |
| WO2021242493A2 (en) | 2021-12-02 |
| JP2023524819A (ja) | 2023-06-13 |
| CN115996752B (zh) | 2025-04-01 |
| AU2021278819A1 (en) | 2022-11-24 |
| EP4146276A4 (en) | 2024-08-14 |
| CA3177879A1 (en) | 2021-12-02 |
| EP4146276A2 (en) | 2023-03-15 |
| WO2021242493A3 (en) | 2022-06-09 |
| US20240034775A1 (en) | 2024-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024000271A (es) | Inhibidor de shp2 y uso del mismo. | |
| MY208545A (en) | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | |
| WO2020104648A3 (en) | TGFβ INHIBITOR AND PRODRUGS | |
| MY206796A (en) | Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma | |
| PH12020551995A1 (en) | Modulator of apol1 expression | |
| PH12021551463A1 (en) | Modulators of hsd17b13 expression | |
| MY194227A (en) | Modulators of pcsk9 expression | |
| NI202100018A (es) | Moduladores de la expresión de pnpla3 | |
| PH12022550130A1 (en) | Enzyme inhibitors | |
| MX2021004819A (es) | Composiciones y metodos para tratar lesiones cerebrales. | |
| MX2019011506A (es) | Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer. | |
| MX2024010804A (es) | Butirato alimenticio para tratar o prevenir un trastorno alergico. | |
| WO2021242493A3 (en) | Compositions and methods for treating epilepsy | |
| PH12022550118A1 (en) | Enzyme inhibitors | |
| BR112022003768A2 (pt) | Compostos inibidores de perk | |
| MX2024008831A (es) | Terapia combinada para carcinoma hepatocelular. | |
| MX2021008918A (es) | Moduladores de expresion yap1. | |
| ZA202103914B (en) | Cxcr7 inhibitors for the treatment of cancer | |
| MX2022008532A (es) | Inhibidores de hidrocarburo de arilo (ahr) y usos de estos. | |
| WO2020086954A3 (en) | Treatments for charcot-marie-tooth disease | |
| PH12021552499A1 (en) | Methods for the treatment of beta-thalassemia | |
| MX2021009535A (es) | Uso de composiciones tópicas de inhibidores de braf para el tratamiento de la dermatitis por radiación. | |
| WO2019173478A3 (en) | Combination of depletes tregs and a checkpoint inhibitor | |
| BR112022001602A2 (pt) | Composição e método para prevenir, aliviar ou tratar lesão hepática | |
| MX2024012789A (es) | Inhibidores de fosfoinositida 3-cinasa alfa (pi3kalfa) |